$Pfizer(PFE)$ yeah yeah yeah.

$Pfizer(PFE)$ yeah yeah yeah. Wayang to the max. But when it comes to a worldwide pandemic anything goes right? Just push it and make max profit, bribe authorities around the world. Who cares if a few of our customers die, right?

Pfizer Yanks Sickle-Cell Treatment Worldwide After Possible Link to Deaths

Pfizer Withdraws Sickle Cell Disease Treatment

Pfizer has voluntarily withdrawn its therapy Oxbryta, used for the treatment of sickle cell disease, from all markets where it is approved. The decision is based on the totality of clinical data, which indicates that the benefit of Oxbryta no longer outweighs the risks associated with its use. Pfizer is discontinuing all active voxelotor clinical trials and expanded access programs worldwide. The company's primary concern is for patients who suffer from sickle cell disease, which remains a serious and diffi

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":353365652533296,"tweetId":"353365652533296","gmtCreate":1727313814993,"gmtModify":1727314037633,"author":{"id":3579827147050987,"idStr":"3579827147050987","authorId":3579827147050987,"authorIdStr":"3579827147050987","name":"xupper22","avatar":"https://static.tigerbbs.com/6b13c95cf147fc91a64e304d76553827","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.08","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[{"themeId":"693c6351429fb5f70a8db1794ff96fa6","categoryId":"2929bb7468f5415f853fd96fb35d7c3b","name":"Pfizer Withdraws Sickle Cell Disease Treatment","type":2,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":693c6351429fb5f70a8db1794ff96fa6}&rnconfig={\"headerBarHidden\": true}","description":"Pfizer has voluntarily withdrawn its therapy Oxbryta, used for the treatment of sickle cell disease, from all markets where it is approved. The decision is based on the totality of clinical data, which indicates that the benefit of Oxbryta no longer outweighs the risks associated with its use. Pfizer is discontinuing all active voxelotor clinical trials and expanded access programs worldwide. The company's primary concern is for patients who suffer from sickle cell disease, which remains a serious and diffi"}],"images":[],"coverImages":[],"html":"<html><head></head><body><p><a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$&nbsp;</a> yeah yeah yeah. Wayang to the max. But when it comes to a worldwide pandemic anything goes right? Just push it and make max profit, bribe authorities around the world. Who cares if a few of our customers die, right?</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$&nbsp;</a> yeah yeah yeah. Wayang to the max. But when it comes to a worldwide pandemic anything goes right? Just push it and make max profit, bribe authorities around the world. Who cares if a few of our customers die, right?</p></body></html>","text":"$Pfizer(PFE)$ yeah yeah yeah. Wayang to the max. But when it comes to a worldwide pandemic anything goes right? Just push it and make max profit, bribe authorities around the world. Who cares if a few of our customers die, right?","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/353365652533296","repostId":2470219752,"repostType":2,"repost":{"id":"2470219752","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1727308430,"share":"https://www.laohu8.com/m/news/2470219752?lang=&edition=full","pubTime":"2024-09-26 07:53","market":"sg","language":"en","title":"Pfizer Yanks Sickle-Cell Treatment Worldwide After Possible Link to Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=2470219752","media":"Dow Jones","summary":"Pfizer looking into data suggesting a potential link to sickle-cell complications and 'fatal events'. Pfizer Inc. said late Wednesday it was withdrawing a sickle-cell drug from markets worldwide and discontinuing clinical trials of the treatment after it investigates data suggesting a potential link to sickle-cell complications and \"fatal events.\". \"Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle-cell patient population,\" the pharma giant said in a statement.\"The data suggest an imbalance in vaso-occlusive crises and fatal events which require further assessment.\" Vaso-occlusive crises are a relatively common complication of sickle-cell anemia.Pfizer  said it does not expect the voluntary action to impact its full-year 2024 financial guidance.Pfizer has notified regulatory authorities about its decision to withdraw the treatment while it further reviews the available data a","content":"<html><head></head><body><p> <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>  looking into data suggesting a potential link to sickle-cell complications and &#39;fatal events&#39;.</p><p>Pfizer Inc. said late Wednesday it was withdrawing a sickle-cell drug from markets worldwide and discontinuing clinical trials of the treatment after it investigates data suggesting a potential link to sickle-cell complications and &#34;fatal events.&#34;</p><p>&#34;Pfizer&#39;s decision is based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle-cell patient population,&#34; the pharma giant said in a statement.</p><p>&#34;The data suggest an imbalance in vaso-occlusive crises and fatal events which require further assessment.&#34; Vaso-occlusive crises are a relatively common complication of sickle-cell anemia.</p><p>Pfizer said it does not expect the voluntary action to impact its full-year 2024 financial guidance.</p><p>Pfizer has notified regulatory authorities about its decision to withdraw the treatment while it further reviews the available data and investigates the findings, it said.</p><p>&#34;The safety and well-being of patients is of the utmost importance to Pfizer, and we believe this action is in the best interest of patients,&#34; Pfizer Chief Medical Officer Aida Habtezion said.</p><p>The company advises patients to discuss alternative treatments with their doctor, as sickle-cell disease remains a serious and difficult-to-treat illness with limited treatment options.</p><p>The Food and Drug Administration granted accelerated approval for Oxbryta tablets in 2019 for adults and teens. In December 2021, the FDA expanded the approved the use for the treatment of children.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Yanks Sickle-Cell Treatment Worldwide After Possible Link to Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Yanks Sickle-Cell Treatment Worldwide After Possible Link to Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-09-26 07:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p> <a href=\"https://laohu8.com/S/PFE\">Pfizer</a>  looking into data suggesting a potential link to sickle-cell complications and &#39;fatal events&#39;.</p><p>Pfizer Inc. said late Wednesday it was withdrawing a sickle-cell drug from markets worldwide and discontinuing clinical trials of the treatment after it investigates data suggesting a potential link to sickle-cell complications and &#34;fatal events.&#34;</p><p>&#34;Pfizer&#39;s decision is based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle-cell patient population,&#34; the pharma giant said in a statement.</p><p>&#34;The data suggest an imbalance in vaso-occlusive crises and fatal events which require further assessment.&#34; Vaso-occlusive crises are a relatively common complication of sickle-cell anemia.</p><p>Pfizer said it does not expect the voluntary action to impact its full-year 2024 financial guidance.</p><p>Pfizer has notified regulatory authorities about its decision to withdraw the treatment while it further reviews the available data and investigates the findings, it said.</p><p>&#34;The safety and well-being of patients is of the utmost importance to Pfizer, and we believe this action is in the best interest of patients,&#34; Pfizer Chief Medical Officer Aida Habtezion said.</p><p>The company advises patients to discuss alternative treatments with their doctor, as sickle-cell disease remains a serious and difficult-to-treat illness with limited treatment options.</p><p>The Food and Drug Administration granted accelerated approval for Oxbryta tablets in 2019 for adults and teens. In December 2021, the FDA expanded the approved the use for the treatment of children.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4592":"伊斯兰概念","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4007":"制药","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","PFE":"辉瑞","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4588":"碎股","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4581":"高盛持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2470219752","content_text":"Pfizer  looking into data suggesting a potential link to sickle-cell complications and 'fatal events'.Pfizer Inc. said late Wednesday it was withdrawing a sickle-cell drug from markets worldwide and discontinuing clinical trials of the treatment after it investigates data suggesting a potential link to sickle-cell complications and \"fatal events.\"\"Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle-cell patient population,\" the pharma giant said in a statement.\"The data suggest an imbalance in vaso-occlusive crises and fatal events which require further assessment.\" Vaso-occlusive crises are a relatively common complication of sickle-cell anemia.Pfizer said it does not expect the voluntary action to impact its full-year 2024 financial guidance.Pfizer has notified regulatory authorities about its decision to withdraw the treatment while it further reviews the available data and investigates the findings, it said.\"The safety and well-being of patients is of the utmost importance to Pfizer, and we believe this action is in the best interest of patients,\" Pfizer Chief Medical Officer Aida Habtezion said.The company advises patients to discuss alternative treatments with their doctor, as sickle-cell disease remains a serious and difficult-to-treat illness with limited treatment options.The Food and Drug Administration granted accelerated approval for Oxbryta tablets in 2019 for adults and teens. In December 2021, the FDA expanded the approved the use for the treatment of children.","news_type":1},"isVote":1,"tweetType":1,"viewCount":356,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["PFE"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":189,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/353365652533296"}